Jaguar health appoints european pharmaceutical industry leader as president of jaguar international

Dr. massimo radaelli's core focus will be on further expanding jaguar's commercial footprint outside the u.s. dr. radaelli was instrumental in facilitating the recent out-license agreement with gen for crofelemer in turkey and 8 neighboring countries that entails a $2.0 million investment in jaguar stock at a premium price san francisco, ca / accesswire / april 2, 2024 / jaguar health, inc. (nasdaq:jagx) ("jaguar") today announced that massimo radaelli, phd, has been appointed president of jaguar international. a european pharmaceutical industry leader and entrepreneur with more than 35 years' experience in the biopharmaceutical sector and innovation in therapies dedicated to rare diseases, dr. radaelli is a member of the board of directors of napo therapeutics, the jaguar family company established in italy in 2021 that focuses on expanding crofelemer access in europe, and temporarily served as napo therapeutics' interim executive director.
JAGX Ratings Summary
JAGX Quant Ranking